Stockscreener 앱 받기
34.47
3.05%
0.99
전일 마감가:
$33.48
열려 있는:
$33.82
하루 거래량:
866.33K
Relative Volume:
0.40
시가총액:
$3.54B
수익:
$164.01M
순이익/손실:
$-65.04M
주가수익비율:
-50.17
EPS:
-0.687
순현금흐름:
$-383.84M
1주 성능:
+1.68%
1개월 성능:
+19.13%
6개월 성능:
+27.12%
1년 성능:
+73.54%
1일 변동 폭
$33.77
$35.74
1주일 범위
$32.84
$36.75
52주 변동 폭
$15.60
$36.88
빔 테라퓨틱스 Stock (BEAM) Company Profile
명칭
Beam Therapeutics Inc
전화
857-327-8775
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
34.44 | 3.53B | 164.01M | -65.04M | -383.84M | -0.687 |
VRTX
Vertex Pharmaceuticals Inc
|
520.68 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
646.22 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
944.59 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
315.56 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.44 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
빔 테라퓨틱스 Stock (BEAM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-20 | 개시 | Canaccord Genuity | Buy |
| 2025-10-09 | 개시 | Jefferies | Buy |
| 2025-03-28 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-03-10 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-07-23 | 개시 | H.C. Wainwright | Buy |
| 2024-01-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-12-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-10-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | 개시 | Citigroup | Buy |
| 2022-06-17 | 개시 | BMO Capital Markets | Market Perform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2022-01-05 | 개시 | Guggenheim | Buy |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-09-24 | 재개 | Stifel | Buy |
| 2021-09-10 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Redburn | Buy |
| 2021-05-04 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-02-16 | 개시 | Wells Fargo | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-08-05 | 개시 | William Blair | Outperform |
| 2020-03-02 | 개시 | Barclays | Overweight |
| 2020-03-02 | 개시 | JP Morgan | Overweight |
| 2020-03-02 | 개시 | Jefferies | Buy |
| 2020-03-02 | 개시 | Wedbush | Outperform |
모두보기
빔 테라퓨틱스 주식(BEAM)의 최신 뉴스
Beam Therapeutics (BEAM) CEO exercises options and sells 50K shares under plan - Stock Titan
BEAMBeam Therapeutics Inc Latest SEC Filings - Finviz
Hedge Fund and Insider Trading News: Paul Singer, Warren Buffett, Ray Dalio, George Soros, Millennium Management, Point72 Asset Management, Citadel Investment Group, CG Oncology Inc (CGON), Beam Therapeutics Inc (BEAM), and More - Insider Monkey
BEAM News | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
Beam Therapeutics(BEAM.US) 10% Shareholder Sells US$10.04 Million in Common Stock - Moomoo
Form 144 BEAM THERAPEUTICS INC. For: 29 June By Investing.com - Investing.com South Africa
FMR LLC sells $10.04 million in Beam Therapeutics shares By Investing.com - Investing.com Australia
BEAM (NASDAQ: BEAM) insider files to sell 25,000 shares via option exercise - Stock Titan
Form 4 Beam Therapeutics Inc For: 29 June By Investing.com - Investing.com Nigeria
FMR LLC sells $10.04 million in Beam Therapeutics shares - Investing.com
FMR LLC (BEAM) trims Beam Therapeutics stake with 284,860-share open-market sale - Stock Titan
Beam Therapeutics Inc.(NasdaqGS: BEAM) added to Russell 2000 Value Benchmark - marketscreener.com
Beam Therapeutics Inc.(NasdaqGS: BEAM) added to Russell 3000E Value Benchmark - marketscreener.com
BEAM Stock's Gains Fade Despite Promising Data Rare Liver Disease Treatment Data - Stocktwits
Beam Therapeutics: A Better Entry Point Is Likely Coming (Rating Downgrade) (NASDAQ:BEAM) - Seeking Alpha
Beam Therapeutics, Inc. Actuals & Estimates (NASDAQ:BEAM) - TradingView
Top Beam Therapeutics (BEAM) Competitors 2026 - MarketBeat
BEAM Forecast — Price Target — Prediction for 2027 - TradingView
Beam Therapeutics, Inc. Actuals & Estimates (BMV:BEAM) - TradingView
Price to sales forward of Beam Therapeutics Inc. – NASDAQ:BEAM - TradingView
Enterprise value to EBIT forward of Beam Therapeutics Inc. – NASDAQ:BEAM - TradingView
Enterprise value to EBITDA forward of Beam Therapeutics Inc. – NASDAQ:BEAM - TradingView
Beam Therapeutics (BEAM) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
The Technical Signals Behind (BEAM) That Institutions Follow - Stock Traders Daily
Wedbush Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $65 - Moomoo
Beam Therapeutics stock soars 21% in three months: Here's why - MSN
Beam Therapeutics president exercises 35,505 options | BEAM Insider Trading - Stock Titan
Beam Therapeutics stock hits 52-week high at 36.66 USD By Investing.com - Investing.com Australia
Beam Therapeutics stock hits 52-week high at 36.66 USD - Investing.com
Clinical: Beam Advances Base Editing For PKU - CRISPR Medicine News
Beam Therapeutics Inc (BEAM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria - The Globe and Mail
Beam Therapeutics (BEAM) Receives FDA Approval for BEAM-304 IND Application - GuruFocus
Beam gets FDA clearance for BEAM-304 PKU gene-editing trial - Stock Titan
Beam Therapeutics gets FDA clearance for BEAM-304 - grafa.com
Beam Therapeutics gets FDA clearance for PKU gene therapy trial - Investing.com
Beam Therapeutics gets FDA clearance for PKU gene therapy trial By Investing.com - Investing.com South Africa
Beam Therapeutics Inc (BEAM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Beam Therapeutics Announces Clearance of Investigational - GlobeNewswire
Beam Therapeutics Inc (BEAM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Beam Therapeutics Inc (BEAM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Beam Therapeutics Inc (BEAM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Beam Therapeutics Inc (BEAM) Institutional Confidence - TradingKey
BEAM Stock Price, Quote & Chart - ChartMill
Beam Therapeutics Stock Soars 21% in Three Months: Here's Why - The Globe and Mail
Is Beam Therapeutics Inc. (BEAM) One of the Best Genomics Stocks to Buy According to Analysts? - Insider Monkey
빔 테라퓨틱스 (BEAM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.42%
자본화:
|
볼륨(24시간):